TEDA BIOMEDICAL (08189) announces a profit alert, expecting a net profit attributable to shareholders of approximately 7 million to 10 million yuan for the interim period, marking a turnaround from loss to profit compared to the same period last year.

TEDA BIOMEDICAL (08189) announced that for the six months ending June 30, 2026, the group expects to achieve: revenue of approximately RMB 290 million to RMB 300 million, an increase of about 28% to 33% compared to revenue of approximately RMB 226 million for the six months ending June 30, 2025 (the same period last year); and net profit attributable to shareholders of approximately RMB 7 million to RMB 10 million, a significant increase of approximately 209% to 256% compared to a net loss of approximately RMB 6 million for the same period last year, thus achieving a turnaround from loss to profit. The growth in revenue and net profit attributable to shareholders during the reporting period is primarily driven by the rapid expansion of the AI life health business. During the reporting period, the AI life health business generated revenue of approximately RMB 100 million to RMB 110 million, with net profit attributable to shareholders of approximately RMB 10 million to RMB 12 million.